| IJCEP Copyright © 2007-All rights reserved. |
Int J Clin Exp Pathol 2010;3(3):280-287
Original Article
CD138 (Syndecan-1) in thymic neoplasms: correlation with various World Health
Organization types and clinical outcome
Al-Agha Osama, Liu Weiguo, Chandrasekhar Rameela, Wilding Gregory, Tan Dongfeng, Alrawi Sadir, Khoury Thaer
Department of pathology, Department of Biostatics, Roswell Park Cancer Institute; Department of Pathology, State University of New York at
Buffalo, Buffalo, NY; Department of Pathology, MD-Anderson Cancer Center, Houston, TX; Department of Surgical Oncology, University of
Florida, Jacksonville, FL, USA.
Received December 27, 2009, accepted February 2, 2010, available online: February 10, 2010
Abstract: We intended to explore the interrelationship of CD138 with thymic neoplasms. A series of 64 thymic neoplasms were studied.
Positive staining was seen in 7 of 8 (87.5%) type A, 7 of 16 (43.7%) type AB, 1 of 8 (12.5%) type B1, 1 of 5 (20%) type B2, 10 of 17 (58.8%) type
B3 and 3 of 10 (30%) type C (p=0.04). While 9 of 10 (90%) CD138 positive type B3 had membranous expression; cytoplasmic expression was
identified in 7 of 7 (100%) type A, and 6 of 7 (86%) type AB (p<0.0001). Positive CD138 was noted in 20 of 31 (64.5%) cases with Masaoka
stage I (p= 0.01); while negative CD138 was seen in 24 of 33 (72.7%) cases with Masaoka stages (II, III or IV). Tumor recurred in 4 cases (7%),
all of which had negative CD138 (p=0.008). CD138 could be used as an ancillary study to differentiate between WHO histologic types. CD138
negativity can also be used as a predictive factor for worse clinical outcome. (IJCEP912008).
Key words: CD138, syndecan-1, thymic tumors, correlation, WHO classification, prognosis
Full text PDF
Address all correspondence to:
Thaer Khoury, M.D.
Roswell Park Cancer Institute,
Elm & Carlton streets
Buffalo, NY 14263
Tel: (716) 845-7700 (ext: 4178)
E-mail: thaer.khoury@roswellpark.org
Original Article
CD138 (Syndecan-1) in thymic neoplasms: correlation with various World Health
Organization types and clinical outcome
Al-Agha Osama, Liu Weiguo, Chandrasekhar Rameela, Wilding Gregory, Tan Dongfeng, Alrawi Sadir, Khoury Thaer
Department of pathology, Department of Biostatics, Roswell Park Cancer Institute; Department of Pathology, State University of New York at
Buffalo, Buffalo, NY; Department of Pathology, MD-Anderson Cancer Center, Houston, TX; Department of Surgical Oncology, University of
Florida, Jacksonville, FL, USA.
Received December 27, 2009, accepted February 2, 2010, available online: February 10, 2010
Abstract: We intended to explore the interrelationship of CD138 with thymic neoplasms. A series of 64 thymic neoplasms were studied.
Positive staining was seen in 7 of 8 (87.5%) type A, 7 of 16 (43.7%) type AB, 1 of 8 (12.5%) type B1, 1 of 5 (20%) type B2, 10 of 17 (58.8%) type
B3 and 3 of 10 (30%) type C (p=0.04). While 9 of 10 (90%) CD138 positive type B3 had membranous expression; cytoplasmic expression was
identified in 7 of 7 (100%) type A, and 6 of 7 (86%) type AB (p<0.0001). Positive CD138 was noted in 20 of 31 (64.5%) cases with Masaoka
stage I (p= 0.01); while negative CD138 was seen in 24 of 33 (72.7%) cases with Masaoka stages (II, III or IV). Tumor recurred in 4 cases (7%),
all of which had negative CD138 (p=0.008). CD138 could be used as an ancillary study to differentiate between WHO histologic types. CD138
negativity can also be used as a predictive factor for worse clinical outcome. (IJCEP912008).
Key words: CD138, syndecan-1, thymic tumors, correlation, WHO classification, prognosis
Full text PDF
Address all correspondence to:
Thaer Khoury, M.D.
Roswell Park Cancer Institute,
Elm & Carlton streets
Buffalo, NY 14263
Tel: (716) 845-7700 (ext: 4178)
E-mail: thaer.khoury@roswellpark.org
 | |  | |  | |  | |  | |  |
